Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab

Retina

Volumn 28, Issue 10, 2008, Pages 1395-1399

  Fintak, David R ^a   Shah, Gaurav K ^a   Blinder, Kevin J ^a   Regillo, Carl D ^b   Pollack, John ^c   Heier, Jeffrey S ^d   Hollands, Hussein ^e   Sharma, Sanjay ^e  

^a BARNES RETINA INSTITUTE   (United States)

^b WILLS EYE HOSPITAL   (United States)

^c Illinois Retina Associates   (United States)

^d OPHTHALMIC CONSULTANTS OF BOSTON   (United States)

^e QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ADULT; AGED; ALPHA HEMOLYTIC STREPTOCOCCUS; AMBULATORY CARE; ARTICLE; BACTERIUM CULTURE; CLINICAL ARTICLE; CLINICAL TRIAL; DIABETIC MACULAR EDEMA; ENDOPHTHALMITIS; EYE EXAMINATION; FOLLOW UP; HUMAN; INCIDENCE; INFECTION RATE; MEDICAL RECORD REVIEW; MULTICENTER STUDY; RETINA MACULA AGE RELATED DEGENERATION; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS MITIS; VISUAL ACUITY; BACTERIAL EYE INFECTION; DRUG ANTAGONISM; INJECTION; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION; VITREOUS BODY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ENDOPHTHALMITIS; EYE INFECTIONS, BACTERIAL; HUMANS; INCIDENCE; INJECTIONS; MIDDLE AGED; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS MITIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VIRIDANS STREPTOCOCCI; VITREOUS BODY;

EID: 58949083350     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181884fd2     Document Type: Article

References (41)

1. Ohm J. Uber die Behandlung der Netzhautablosung durch operative Entleerung der subretinalen Flossigkeit und Einspritzung von Luft in den Glaskorper. Albrecht Von Graefes Arch Ophthalmol 1911;79:442- 450.
2. Soheilian M, Rafati N, Mohebbi MR, et al. Traumatic Endophthalmitis Trial Research Group. Prophylaxis of acute posttraumatic bacterial endophthalmitis: a multicenter, randomized clinical trial of intraocular antibiotic injection, report 2. Arch Ophthalmol 2007;125:460-465.
3. Chen FK, Chen SD, Tay-Kearney ML. Intravitreal voriconazole for the treatment of endogenous endophthalmitis caused by Scedosporium apiospermum. Clin Experiment Ophthalmol 2007;35:382-385.
4. Sen P, Gopal L, Sen PR. Intravitreal voriconazole for drug-resistant fungal endophthalmitis: case series. Retina 2006;26: 935-939.
5. Kramer M, Kramer MR, Blau H, et al. Intravitreal voriconazole for the treatment of endogenous Aspergillus endophthalmitis. Ophthalmology 2006;113:1184-1186.
6. Talamo JH, D'Amico DJ, Kenyon KR. Intravitreal amikacin in the treatment of bacterial endophthalmitis. Arch Ophthalmol 1986;104:1483-1485.
7. Baum J, Peyman GA, Barza M. Intravitreal administration of antibiotic in the treatment of bacterial endophthalmitis. III. Consensus. Surv Ophthalmol 1982;26:204 -206.
8. Forster RK, Zachary IG, Cottingham AJ Jr, Norton EWD. Further observations on the diagnosis, cause, and treatment of endophthalmitis. Am J Ophthalmol 1976;81:52-56.
9. Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol 1995;113:1479-1496.
10. Ausayakhun S, Yuvaves P, Ngamtiphakom S, Prasitsilp J. Treatment of cytomegalovirus retinitis in AIDS patients with intravitreal ganciclovir. J Med Assoc Thai 2005;88:S15-S20.
11. Baudouin C, Chassain C, Caujolle C, Gastaud P. Treatment of cytomegalovirus retinitis in AIDS patients using intravitreal injections of highly concentrated ganciclovir. Ophthalmo-logica 1996;210:329-335.
12. Velez G, Roy CE, Whitcup SM, Chan CC, Robinson MR. High-dose intravitreal ganciclovir and foscarnet for cytomegalovirus retinitis. Am J Ophthalmol 2001;131:396-397.
13. Tognon MS, Turrini B, Masiero G, et al. Intravitreal and systemic foscarnet in the treatment of AIDS-related CMV retinitis. Eur J Ophthalmol 1996;6:179-182.
14. Henry K, Cantrill H, Fletcher C, Chinnock BJ, Balfour HH Jr. Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS. Am J Ophthalmol 1987;103:17-23.
15. King J, Chung M, Diloreto DA Jr. A 9 year-old girl with herpes simplex virus type 2 acute retinal necrosis treated with intravitreal foscarnet. Ocul Immunol Inflamm 2007; 15:395-398.
16. Yin PD, Kurup SK, Fischer SH, et al. Progressive outer retinal necrosis in the era of highly active antiretroviral therapy: successful management with intravitreal injections and monitoring with quantitative PCR. J Clin Virol 2007;38:254 -259.
17. Meffert SA, Kertes PJ, Lim PL, Conway MD, Peyman GA. Successful treatment of progressive outer retinal necrosis using high-dose intravitreal ganciclovir. Retina 1997;17: 560-562.
18. Martidis A, Duker JS, Puliafito CA. Intravitreal triamcinolone for refractory cystoid macular edema secondary to birdshot retinochoroidopathy. Arch Ophthalmol 2001;119:1380-1383.
19. Tuncer S, Yilmaz S, Urgancioglu M, Tugal-Tutkun I. Results of intravitreal triamcinolone acetonide (IVTA) injection for the treatment of panuveitis attacks in patients with Behcet disease. J Ocul Pharmacol Ther 2007;23:395-401.
20. Aggio FB, Muccioli C, Belfort R Jr. Intravitreal triamcinolone acetonide as an adjunct in the treatment of severe ocular toxoplasmosis. Eye 2006;20:1080 -1082.
21. Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, Ffytche TJ, Marshall J. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology 2001;108:765-772.
22. Young S, Larkin G, Branley M, Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular edema in uveitis. Clin Exp Ophthalmol 2001;29:2-6.
23. Liggett PE, Colina J, Chaudhry NA, Tom D, Haffner G. Triple therapy of intravitreal triamcinolone, photodynamic therapy, and pegaptanib sodium for choroidal neovascularization. Am J Ophthalmol 2006;142:1072-1074.
24. Gillies MC, Larsson J. The effect of intravitreal triamcinolone on foveal edema in exudative macular degeneration. Am J Ophthalmol 2007;144:134 -136.
25. Batioglu F, Ozmert E, Parmak N, Celik S. Two-year results of intravitreal triamcinolone acetonide injection for the treatment of diabetic macular edema. Int Ophthalmol 2007;27:299-306.
26. Ramezani A, Entezari M, Moradian S, Tabatabaei H, Kad-khodaei S. Intravitreal triamcinolone for acute central retinal vein occlusion; a randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 2006;244:1601-1606.
27. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002;109:920-927.
28. Greenberg PB, Martidis A, Rogers AH, Duker JS, Reichel E. Intravitreal triamcinolone acetonide for macular edema due to central retinal vein occlusion. Br J Ophthalmol 2002;86: 247-248.
29. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular agerelated macular degeneration. N Engl J Med 2004;351:2805- 2816.
30. Rosenfeld PJ, Brown DM, Heier JS, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
31. Brown DM, Kaiser PK, Michels M, et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432- 1444.
32. Fung AE, Rosenfeld PJ, Reichel E. The International Intra-vitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344- 1349.
33. Jonas JB, Spandau UH, Rensch F, Von Baltz S, Schlichtenbrede F. Infectious and noninfectious endophthalmitis after intravitreal bevacizumab. J Ocul Pharmacol Ther 2007;23: 240-242.
34. Young SH, Morlet N, Heery S, Hollows FC, Coroneo MT. High dose intravitreal ganciclovir in the treatment of cytomeg-alovirus retinitis. Med J Aust 1992;157:370-373.
35. Jager RD, Aiello LP, Patel SC, Cunningham ET Jr. Risks of intravitreous injection: a comprehensive review. Retina 2004; 24:676-698.
36. Engstrom RE, Holland GN. Local therapy for cytomegalovirus retinopathy. Am J Ophthalmol 1995;120:376-385.
37. Moshfeghi DM, Kaiser PK, Scott IU, et al. Acute endoph-thalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2003;136:791-796.
38. Westfall AC, Osborn A, Kuhl D, Benz MS, Mieler WF, Holz ER. Acute endophthalmitis incidence-intravitreal triamcino-lone. Arch Ophthalmol 2005;123:1075-1077.
39. Nelson ML, Tennant MT, Sivalingam A, Regillo CD, Belmont JB, Martidis A. Infectious and presumed noninfectious en-dophthalmitis after intravitreal triamcinolone acetonide injection. Retina 2003;23:686-691.
40. Tornambe PE, Hilton GF. The Retinal Detachment Study Group. Pneumatic retinopexy. A multicenter randomized controlled clinical trial comparing pneumatic retinopexy with scleral buckling. Ophthalmology 1989;96:772-784.
41. Hilton GF, Kelly NE, Salzano TC, Tornambe PE, Wells JW, Wendel RT. Pneumatic retinopexy. A collaborative report of the first 100 cases. Ophthalmology 1987;94:307-314.